HUTCHMED (China) Ltd (FRA:H7T1)
€ 16.4 -0.7 (-4.09%) Market Cap: 2.80 Bil Enterprise Value: 2.13 Bil PE Ratio: 0 PB Ratio: 4.05 GF Score: 66/100

Hutchison China MediTech Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 01:00PM GMT
Release Date Price: €29.2 (+0.69%)
David Lau
JPMorgan Chase & Co. - Head of China Investment Banking Coverage

Good morning, everyone. My name is David Lau from JPMorgan Hong Kong Investment Banking. Today, we are absolutely honored to have Mr. Christian Hogg from Hutchison Chi-Med to present at the 2021 JPMorgan Healthcare Conference. Chi-Med, as we call it, is an innovative, commercial-stage biopharmaceutical company that is committed to the discovery and development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

It has a portfolio of 9 cancer drug candidates in clinical studies around the world, and a scientific team of over 490 people. Our speaker today, Mr. Christian Hogg, is the CEO of the company, who joined in year 2000 as the first employee of the company. He is, therefore, the best person to talk about the company.

So without further ado, I will pass it on to Christian for the presentation. Thank you.

Christian Hogg
Hutchison China MediTech Limited - CEO & Executive Director

Thank you, David. That's a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot